Euro vs US Dollar

Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.

Registrieren

VTGN Vistagen Therapeutics Inc

3,35

-0,17 (-4,83%)

15 Jun 2024 - Geschlossen

Verzögert um 15 Minuten

Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individuals

Vistagen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
Von Mai 2024 bis Jun 2024

Click Here for more Vistagen Therapeutics Charts.

Vistagen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
Von Jun 2023 bis Jun 2024

Click Here for more Vistagen Therapeutics Charts.

News VistaGen Therapeutics Inc

Form 8-K - Current report
Dienstag 11 Juni 2024 (5 Tage vor) • Edgar (US Regulatory)

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Dienstag 11 Juni 2024 (5 Tage vor) • Edgar (US Regulatory)

Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update
Dienstag 11 Juni 2024 (5 Tage vor) • Business Wire

U.S. Index Futures Fall Ahead of Federal Reserve Policy Meeting, Crude Oil Prices Decline
Dienstag 11 Juni 2024 (6 Tage vor) • IH Market News

Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024
Freitag 7 Juni 2024 (1 Woche vor) • Business Wire

Form 8-K - Current report
Freitag 31 Mai 2024 (2 Wochen vor) • Edgar (US Regulatory)

Vistagen to Present at the Jefferies Global Healthcare Conference
Mittwoch 29 Mai 2024 (3 Wochen vor) • Business Wire

Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference
Donnerstag 23 Mai 2024 (4 Wochen vor) • Business Wire

Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference
Dienstag 7 Mai 2024 (1 Monat vor) • Business Wire

Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue
Donnerstag 25 April 2024 (2 Monate vor) • Business Wire

Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference
Dienstag 9 April 2024 (2 Monate vor) • Business Wire

Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2
Montag 1 April 2024 (3 Monate vor) • Business Wire

Weitere VistaGen Therapeutics Inc News-Artikel

BNP Paribas Issuance

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen